Harrow Inc. (HROW) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, HROW scores 55 out of 100 with a letter grade of D+ and the verdict "Roarable Sell — Weak Fundamentals / Trim." The fundamental cash engine pillar scores 18 of 20, supported by ROIC of 42.9% and an FCF yield of 3.82%; this is the strongest pillar and indicates the business generates substantial return on invested capital relative to the figures in the source. The forensic balance sheet pillar scores 12 of 20, with an Altman Z-Score of 2.67, a Piotroski F-Score of 7 of 9, and Debt/Equity of 0.5. The insider conviction pillar scores 13 of 20 based on SEC Form 4 and Congressional PTR cluster flow. The whale 13F flow pillar scores 5 of 20, reflecting institutional accumulation and options positioning. The macro regime fit pillar scores 7 of 20, with a beta of 1.0 and sector sensitivity as the stated driver. For a prospective investor evaluating the stock today, the rating points to a profitable-looking operating engine offset by weak institutional and macro-fit signals; the verdict label itself recommends trimming rather than accumulating. Valuation tradeoffs are visible in the EV/EBITDA multiple of 33.6, which is elevated relative to the rating's cash-generation metrics, and the stock sits near the lower portion of its 52-week range.

Per the SEC financials, revenue grew from $130.2M in FY 2023 to $272.3M in FY 2025, and operating income moved from $0.4M to $30.5M over the same span, while net income remained negative in each period, with the FY 2025 figure at $-5.1M. Net margin per the market data section is -1.9%. Per the Roarable RQD rating, ROIC is 42.9%, the Altman Z-Score is 2.67, and the Piotroski F-Score is 7 of 9, with Debt/Equity of 0.5. Cash rose to $72.9M in FY 2025 per the SEC financials.

Per the recent news wire, six items are tagged with a YELLOW light and MARKET WIRE impact label. Headlines reference options positioning ("Do Options Traders Know Something About Harrow Stock We Don't?"), valuation and conference interest in the ophthalmic pipeline, a Q3 turnaround test, a stock forecast page, a 52-week low at 28.51 USD, and a report of a 32% three-month decline alongside a BTIG 106% upside view. Risk watch items per these headlines include the 52-week low and the cited three-month drawdown. Per the Butterfly Supply-Chain Graph, no supply chain links or proprietary signals are recorded: supply_chain is NONE, and butterfly_links and proprietary_signals are empty.

• What are the company's specific products, revenue segments, and customer concentration? The source data identifies sector and industry only.
• What is the TTM EPS and forward earnings outlook, given that P/E and EPS fields are unavailable?
• What is the composition of debt and the cash position for FY 2024 and FY 2025, given that debt is N/A in all periods?
• What drove the reported net losses despite improving operating income in each period?
• What institutional, insider, and analyst activity underlies the RQD whale and insider pillar scores, given that holders and analyst data are absent?